5-羟色胺和去さ甲かぶと肾上腺せん素もと再さい摄取抑制よくせい剂

5-羟色胺和去さ甲かぶと肾上腺せん素もと再さい摄取抑制よくせい剂（英語えいご：SNRIs, Serotonin–norepinephrine reuptake inhibitors），是ぜ一种用来治疗重度じゅうど抑そもそも郁いく症しょう和かず其他精神せいしん障碍しょうがい的てき抗こう抑そもそも郁いく药。SNRI有ゆう时候也用来らい治ち疗焦こげ虑症，强迫きょうはく症しょう，多た动症，慢性まんせい神かみ经性疼痛とうつう，躯むくろ体たい化か障碍しょうがい，纤维肌はだ痛つう综合征せい和かず缓解更年期こうねんき症状しょうじょう。

SNRI是ぜ高だか效こう的てき5-羟色胺和わ去さ甲かぶと肾上腺せん素もと再さい摄取抑制よくせい剂。^[1]已やめ知ち这些神かみ经递质在ざい控ひかえ制せい情じょう绪时发挥着ぎ重要じゅうよう的てき作用さよう。 SNRI比ひ使用しよう更さら广泛但ただし只ただ能のう单独作用さよう于5-羟色胺的选择性せい5-羟色胺再摄取抑制よくせい剂（SSRI）作用さよう更さら多た。

Timeline-SNRIs-2010 — 已やめ批准ひじゅん的てきSNRI时间线图

活性かっせい成分せいぶん	药品名称めいしょう	治ち疗用途ようと	受体亲和力りょく (K_i, nm)	结构
文ぶん拉ひしげ法ほう辛からし（Venlafaxine）	怡诺思おもえ（Efexor）	重じゅう性せい抑そもそも郁いく障碍しょうがい，包括ほうかつ对其他た治ち疗没反はん应的患者かんじゃ，广泛性せい焦こげ虑症，慢性まんせい疼痛とうつう综合症しょう^[2]	5-HT:7.8 NE:1920 D:6050 ^[3]
米べい那な普ひろし仑（Milnacipran）	Savella, Ixel, Dalcipran, Toledomin	纤维肌はだ痛つう综合征せい及其并发症しょう，重度じゅうど抑そもそも郁いく障碍しょうがい^[4]	5-HT:8.4 NE:22 D:>100000^[3]	Milnacipran
度ど洛らく西にし汀なぎさ（Duloxetine）	Cymbalta, Ariclaim, Xeristar, Yentreve	重度じゅうど抑そもそも郁いく障碍しょうがい和わ纤维肌はだ痛つう综合征せい^[5]	5-HT:0.07 NE:1.2 D:230^[3]	Duloxetine
左ひだり旋米那な普ひろし倫りん	Fetzima	成人せいじん重度じゅうど抑そもそも郁いく障碍しょうがい	5-HT:NA NE:NA D:NA	Levomilnacipran
去さ甲かぶと文ぶん拉ひしげ法ほう辛からし（Desvenlafaxine）	Pristiq	成人せいじん重度じゅうど抑そもそも郁いく障碍しょうがい^[6]	5-HT:61.4 NE:2953 D:NA
西にし布ぬの曲きょく明あきら（Sibutramine）	Meridia, Reductil	肥こえ胖ゆたか^[7]	5-HT:298 NE:5451 D:943

5-HT: 5-羟色胺- NE: 去さ甲かぶと肾上腺せん素もと- D: 多た巴ともえ胺- NA: 不ふ可用かよう

引用いんよう[编辑]

^ Cashman, JR; Ghirmai, S. Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorganic & Medicinal Chemistry. 2009, 17 (19): 6890–7. PMID 19740668. doi:10.1016/j.bmc.2009.08.025.
^ Gutierrez, MA; Stimmel, GL; Aiso, JY. Venlafaxine: A 2003 update. Clinical Therapeutics. 2003, 25 (8): 2138–54. PMID 14512125. doi:10.1016/s0149-2918(03)80210-2.
^ ^3.0 ^3.1 ^3.2 Stahl, SM; Grady, MM; Moret, C; Briley, M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums. 2005, 10 (9): 732–47. PMID 16142213.
^ Morishita, Shigeru; Arita, Seizaburo. The clinical use of milnacipran for depression. European Psychiatry. 2003, 18 (1): 34–5. PMID 12648895. doi:10.1016/S0924-9338(02)00003-2.
^ Hunziker, ME; Suehs, BT; Bettinger, TL; Crismon, ML. Duloxetine hydrochloride: A new dual-acting medication for the treatment of major depressive disorder. Clinical Therapeutics. 2005, 27 (8): 1126–43. PMID 16199241. doi:10.1016/j.clinthera.2005.08.010.
^ Perry, R; Cassagnol, M. Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clinical Therapeutics. 2009, 31 (1): 1374–404. PMID 19698900. doi:10.1016/j.clinthera.2009.07.012.
^ Luque, CA; Rey, JA. The discovery and status of sibutramine as an anti-obesity drug. European Journal of Pharmacology. 2002, 440 (2–3): 119–28. PMID 12007530. doi:10.1016/S0014-2999(02)01423-1.

[Cashman,_J._R._and_Ghirmai,_S._(2009)._Inhibition_of_serotonin_and_norepinephrine_reuptake_and_inhibition_of_phosphodiesterase_by_multi-target_inhibitors_as_potential_agents_for_depression._''Bioorganic_&_Medicinal_Chemistry,_17'',_6890–6897_PMID_19740668-1] Cashman, JR; Ghirmai, S. Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorganic & Medicinal Chemistry. 2009, 17 (19): 6890–7. PMID 19740668. doi:10.1016/j.bmc.2009.08.025.

[Gutierrez-2] Gutierrez, MA; Stimmel, GL; Aiso, JY. Venlafaxine: A 2003 update. Clinical Therapeutics. 2003, 25 (8): 2138–54. PMID 14512125. doi:10.1016/s0149-2918(03)80210-2.

[Stahl-3] 3.0 ^3.1 ^3.2 Stahl, SM; Grady, MM; Moret, C; Briley, M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums. 2005, 10 (9): 732–47. PMID 16142213.

[Morishita-4] Morishita, Shigeru; Arita, Seizaburo. The clinical use of milnacipran for depression. European Psychiatry. 2003, 18 (1): 34–5. PMID 12648895. doi:10.1016/S0924-9338(02)00003-2.

[Hunziker-5] Hunziker, ME; Suehs, BT; Bettinger, TL; Crismon, ML. Duloxetine hydrochloride: A new dual-acting medication for the treatment of major depressive disorder. Clinical Therapeutics. 2005, 27 (8): 1126–43. PMID 16199241. doi:10.1016/j.clinthera.2005.08.010.

[Perry-6] Perry, R; Cassagnol, M. Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clinical Therapeutics. 2009, 31 (1): 1374–404. PMID 19698900. doi:10.1016/j.clinthera.2009.07.012.

[Luque-7] Luque, CA; Rey, JA. The discovery and status of sibutramine as an anti-obesity drug. European Journal of Pharmacology. 2002, 440 (2–3): 119–28. PMID 12007530. doi:10.1016/S0014-2999(02)01423-1.

[1]

[2]

[3]

[4]

[5]

[6]

[7]